CONSORTIUM CALL 2026
The 2026 Milner Therapeutics Consortium Call has now closed.
Our pharma partners in the Milner Therapeutics Consortium work together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.
The 2026 Consortium Call closed on 13 March. It sought project proposals for challenges in:
- Oncology
- Neuroscience
- Immunology and inflammation
- New technologies that will aid therapeutic discovery
- Metabolic and cardiovascular disease
- Dermatology
- Infectious disease
- Expertise e.g. in particular techniques, disease areas, target selection and validation
- Support for pilot (e.g. 6-12 months) or longer-term projects (2-3 years)
- Funding e.g. for a research associate and consumables
- Access to company reagents where appropriate e.g. tool compounds, compound libraries
The Consortium Call is a competitive process; although many proposals will not result in a funded project in the short term, these introductions are a good opportunity to make connections and build a relationship with pharma partners, as well as to receive useful feedback from the pharma perspective.
Contact us
If you have any questions, please email consortium@milner.cam.ac.uk